This trial is active, not recruiting.

Condition infertility
Treatments 10000 iu urinary hcg, 250 mcg recombinant hcg
Phase phase 4
Sponsor Universitair Ziekenhuis Brussel
Collaborator Merck Serono International SA
Start date August 2005
End date December 2006
Trial size 130 participants
Trial identifier NCT00953628, recHCG001


The purpose of this study is to investigate any potential advantages of replacing human chorionic gonadotropin (uhCG) with recombinant human chorionic gonadotropin (recHCG) for final oocyte maturation with regard to Ovarian hyperstimulation syndrome (OHSS)pathophysiology, endometrium receptivity and embryo quality and clinical pregnancy.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking single blind (investigator)
Primary purpose treatment
(Active Comparator)
10000 iu urinary hcg
bolus 10000 units for ovulation triggering
250 mcg recombinant hcg
bolus 250 mcg for ovulation triggering in IVF patients

Primary Outcomes

endometrium histology on the day of OPU
time frame: day of oocytre pick up

Secondary Outcomes

pregnancy rate
time frame: 14 days after oocyte pick up

Eligibility Criteria

Female participants from 20 years up to 36 years old.

Inclusion Criteria: - Less than 36 years old - Male or tubal infertility - FSH<12 on day 3 Exclusion Criteria: - Endometriosis stage 3 & 4

Additional Information

Official title Endometrial Advancement After Rec or u-HCG Triggering
Trial information was received from ClinicalTrials.gov and was last updated in September 2009.
Information provided to ClinicalTrials.gov by Universitair Ziekenhuis Brussel.